CN114430743A - 甲状腺激素受体β激动剂化合物 - Google Patents
甲状腺激素受体β激动剂化合物 Download PDFInfo
- Publication number
- CN114430743A CN114430743A CN202080066442.XA CN202080066442A CN114430743A CN 114430743 A CN114430743 A CN 114430743A CN 202080066442 A CN202080066442 A CN 202080066442A CN 114430743 A CN114430743 A CN 114430743A
- Authority
- CN
- China
- Prior art keywords
- compound
- mixture
- pharmaceutically acceptable
- acceptable salt
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891078P | 2019-08-23 | 2019-08-23 | |
| US62/891,078 | 2019-08-23 | ||
| US202062967943P | 2020-01-30 | 2020-01-30 | |
| US62/967,943 | 2020-01-30 | ||
| PCT/US2020/047467 WO2021041237A1 (en) | 2019-08-23 | 2020-08-21 | Thyroid hormone receptor beta agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114430743A true CN114430743A (zh) | 2022-05-03 |
Family
ID=74684314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080066442.XA Pending CN114430743A (zh) | 2019-08-23 | 2020-08-21 | 甲状腺激素受体β激动剂化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12528791B2 (https=) |
| EP (1) | EP4017875A4 (https=) |
| JP (2) | JP7646632B2 (https=) |
| CN (1) | CN114430743A (https=) |
| AU (1) | AU2020336272A1 (https=) |
| CA (1) | CA3154488A1 (https=) |
| WO (1) | WO2021041237A1 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114075173A (zh) * | 2020-08-19 | 2022-02-22 | 成都凡诺西生物医药科技有限公司 | 腈代三嗪类衍生物及其制备方法和应用 |
| US12398127B2 (en) | 2019-09-12 | 2025-08-26 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN120923503A (zh) * | 2025-10-10 | 2025-11-11 | 吉斯凯(苏州)制药有限公司 | 具有杂环结构的化合物、THRβ受体激动剂及用途 |
| US12485118B2 (en) | 2023-04-07 | 2025-12-02 | Terns Pharmaceuticals, Inc. | Combinations of GLP-1R and THRβ agonists and methods of use thereof |
| US12528791B2 (en) | 2019-08-23 | 2026-01-20 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| GEP20247637B (en) | 2019-05-08 | 2024-06-25 | Aligos Therapeutics Inc | Modulators of thr-b and methods of use thereof |
| AU2021306314A1 (en) | 2020-07-10 | 2023-02-09 | Aligos Therapeutics, Inc. | Modulators of THR-β and methods of use thereof |
| CA3212130A1 (en) * | 2021-03-03 | 2022-09-09 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2022194278A1 (zh) * | 2021-03-19 | 2022-09-22 | 南京明德新药研发有限公司 | 双环苯酚类化合物及其应用 |
| WO2022242743A1 (zh) * | 2021-05-21 | 2022-11-24 | 深圳微芯生物科技股份有限公司 | 一种杂环化合物及其应用 |
| CN113979963B (zh) * | 2021-12-24 | 2022-03-11 | 凯思凯旭(上海)医药科技有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| TWI910297B (zh) * | 2021-12-24 | 2026-01-01 | 大陸商廣東東陽光藥業股份有限公司 | 一種作為甲狀腺激素β受體激動劑的化合物及其用途 |
| CN116354934A (zh) * | 2021-12-28 | 2023-06-30 | 中国科学院上海药物研究所 | 一类喹啉类化合物及其制备方法、药物组合物和用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157844A1 (en) * | 1999-09-30 | 2004-08-12 | Dow Robert L. | 6-azauracil derivatives as thyroid receptor ligands |
| WO2007009913A1 (en) * | 2005-07-21 | 2007-01-25 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives as thyroid hormone receptor agonists |
| WO2007134864A1 (en) * | 2006-05-24 | 2007-11-29 | Karo Bio Ab | Indole derivatives and their use as thyroid receptor ligands |
| WO2009037172A1 (en) * | 2007-09-20 | 2009-03-26 | F. Hoffmann-La Roche Ag | Prodrugs to thyroid hormone analogs |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197307A (en) | 1977-04-12 | 1980-04-08 | Ciba-Geigy Corporation | 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents |
| EP0377903A3 (de) | 1989-01-09 | 1991-07-17 | Bayer Ag | Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung |
| EP1088819B1 (en) | 1999-09-30 | 2005-06-15 | Pfizer Products Inc. | 6-azauracil derivatives as thyroid receptor ligands |
| GB0015205D0 (en) | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
| WO2002051805A1 (de) | 2000-12-27 | 2002-07-04 | Bayer Aktiengesellschaft | Indol-derivate |
| US7230031B2 (en) | 2002-01-30 | 2007-06-12 | Kissei Pharmaceutical Co., Ltd. | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| FR2882750B1 (fr) | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| GB0513692D0 (en) * | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| GB0608724D0 (en) * | 2006-05-03 | 2006-06-14 | Karobio Ab | Novel Pharmaceutical Compositions |
| WO2007132475A1 (en) | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
| US8394811B2 (en) | 2007-04-18 | 2013-03-12 | Molsoft Llc | Hydrazide compounds as thyroid hormone receptor modulators and uses thereof |
| WO2009001359A2 (en) | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| FR2933979B1 (fr) | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| TWI534144B (zh) | 2009-04-20 | 2016-05-21 | 田邊三菱製藥股份有限公司 | 甲狀腺荷爾蒙β受體作動藥 |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| EP2780338B1 (en) | 2011-11-14 | 2016-11-09 | Ignyta, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| LT4406594T (lt) | 2012-09-17 | 2025-12-29 | Madrigal Pharmaceuticals, Inc. | Skydliaukės hormono analogai |
| BR112016023269A8 (pt) | 2014-04-11 | 2021-06-29 | Cymabay Therapeutics Inc | uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica |
| EP3189046B1 (en) | 2014-09-05 | 2020-08-26 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| CN105477636B (zh) | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| JPWO2017170434A1 (ja) | 2016-03-28 | 2019-01-31 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｆｘｒアゴニストとａｒｂの組み合わせ医薬 |
| HRP20250776T1 (hr) | 2016-03-31 | 2025-08-29 | Genfit | Elafibranor za uporabu u liječenju primarnog bilijarnog kolangitisa |
| BR112018073460A2 (pt) | 2016-05-25 | 2019-07-09 | Akarna Therapeutics Ltd | terapias combinadas usando moduladores do receptor farnesoide x (fxr) |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| IL266054B2 (en) * | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
| BR112019005930A2 (pt) | 2016-10-19 | 2019-06-11 | Boehringer Ingelheim Int | combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas |
| WO2018103624A1 (zh) | 2016-12-06 | 2018-06-14 | 江苏恒瑞医药股份有限公司 | 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途 |
| KR20190117632A (ko) | 2017-02-21 | 2019-10-16 | 장피트 | Ppar 효현제와 fxr 효현제의 병용 |
| KR20190122806A (ko) | 2017-03-13 | 2019-10-30 | 장피트 | 조합 치료요법용 약학 조성물 |
| US20200131129A1 (en) | 2017-03-15 | 2020-04-30 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| CN110536682B (zh) | 2017-04-18 | 2023-01-06 | 基恩菲特公司 | 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合 |
| WO2018208707A1 (en) | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US20210121493A1 (en) | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| JP2020531023A (ja) | 2017-08-25 | 2020-11-05 | ジェンフィットＧｅｎｆｉｔ | 非アルコール性脂肪性肝疾患、非アルコール性脂肪性肝炎、及び／又は肝線維症の非侵襲的診断 |
| WO2019053235A1 (en) | 2017-09-15 | 2019-03-21 | Genfit | NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS |
| EA202090715A1 (ru) | 2017-09-18 | 2020-07-15 | Женфит | Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени |
| CN111511731B (zh) | 2017-11-01 | 2023-05-23 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的烯烃化合物 |
| ES2986647T3 (es) | 2017-11-13 | 2024-11-12 | Gilead Sciences Inc | Método de estadificación de la fibrosis hepática en pacientes con EHNA |
| CN109574995B (zh) * | 2018-01-23 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| CA3101274A1 (en) | 2018-04-24 | 2019-10-31 | Ph Pharma Co., Ltd. | Use of neutrophil elastase inhibitors in liver disease |
| CN111801324B (zh) | 2018-06-12 | 2021-10-22 | 四川海思科制药有限公司 | 甲状腺激素受体激动剂及其用途 |
| CA3110520A1 (en) | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| SG11202101863YA (en) | 2018-08-30 | 2021-03-30 | Terns Pharmaceuticals Inc | Treating liver disorders |
| IL281427B2 (en) | 2018-09-18 | 2026-01-01 | Terns Inc | Compounds that inhibit tyrosine kinase activity for use in the treatment of leukemia |
| EA202190661A1 (ru) | 2018-09-18 | 2021-08-13 | Метакрайн, Инк. | Агонисты фарнезоидного х-рецептора для лечения заболевания |
| TWI840423B (zh) | 2018-10-12 | 2024-05-01 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| US12391677B2 (en) | 2018-10-12 | 2025-08-19 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020131578A2 (en) | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CN111484481A (zh) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | 哒嗪酮类衍生物、其制备方法及其在医药上的用途 |
| US12338206B2 (en) | 2019-02-21 | 2025-06-24 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as thyroid hormone receptor agonists |
| GEP20247637B (en) | 2019-05-08 | 2024-06-25 | Aligos Therapeutics Inc | Modulators of thr-b and methods of use thereof |
| WO2020228577A1 (zh) | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| CN114174282A (zh) | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| KR20220038368A (ko) | 2019-07-23 | 2022-03-28 | 노파르티스 아게 | Fxr 작용제를 이용하는 간 질환의 병용 치료 |
| CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN114375193B (zh) | 2019-09-12 | 2024-05-14 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
| WO2021121210A1 (zh) | 2019-12-16 | 2021-06-24 | 江苏恒瑞医药股份有限公司 | 并环类衍生物、其制备方法及其在医药上的应用 |
| US20210379040A1 (en) | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| IL298144A (en) | 2020-05-13 | 2023-01-01 | Terns Pharmaceuticals Inc | Combination treatment of liver disorders |
| IL302099A (en) | 2020-10-15 | 2023-06-01 | Lilly Co Eli | Polymorphs of an fxr agonist |
| CN114437034A (zh) | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| CA3212130A1 (en) | 2021-03-03 | 2022-09-09 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2022194278A1 (zh) | 2021-03-19 | 2022-09-22 | 南京明德新药研发有限公司 | 双环苯酚类化合物及其应用 |
| JP2024544538A (ja) | 2021-11-11 | 2024-12-03 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | ＴＨＲ－βアゴニストによる肝障害の治療 |
| TW202327589A (zh) | 2021-11-11 | 2023-07-16 | 美商拓臻製藥公司 | 肝病之組合療法 |
| CA3238102A1 (en) | 2021-11-11 | 2023-05-19 | Terns Pharmaceuticals, Inc. | Treating liver disorders with an ssao inhibitor |
| WO2023220404A1 (en) | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
-
2020
- 2020-08-21 AU AU2020336272A patent/AU2020336272A1/en active Pending
- 2020-08-21 WO PCT/US2020/047467 patent/WO2021041237A1/en not_active Ceased
- 2020-08-21 JP JP2022512349A patent/JP7646632B2/ja active Active
- 2020-08-21 US US17/637,426 patent/US12528791B2/en active Active
- 2020-08-21 EP EP20856291.8A patent/EP4017875A4/en active Pending
- 2020-08-21 CN CN202080066442.XA patent/CN114430743A/zh active Pending
- 2020-08-21 CA CA3154488A patent/CA3154488A1/en active Pending
-
2025
- 2025-03-05 JP JP2025034294A patent/JP2025106242A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157844A1 (en) * | 1999-09-30 | 2004-08-12 | Dow Robert L. | 6-azauracil derivatives as thyroid receptor ligands |
| WO2007009913A1 (en) * | 2005-07-21 | 2007-01-25 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives as thyroid hormone receptor agonists |
| WO2007134864A1 (en) * | 2006-05-24 | 2007-11-29 | Karo Bio Ab | Indole derivatives and their use as thyroid receptor ligands |
| WO2009037172A1 (en) * | 2007-09-20 | 2009-03-26 | F. Hoffmann-La Roche Ag | Prodrugs to thyroid hormone analogs |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12528791B2 (en) | 2019-08-23 | 2026-01-20 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| US12398127B2 (en) | 2019-09-12 | 2025-08-26 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN114075173A (zh) * | 2020-08-19 | 2022-02-22 | 成都凡诺西生物医药科技有限公司 | 腈代三嗪类衍生物及其制备方法和应用 |
| US12485118B2 (en) | 2023-04-07 | 2025-12-02 | Terns Pharmaceuticals, Inc. | Combinations of GLP-1R and THRβ agonists and methods of use thereof |
| CN120923503A (zh) * | 2025-10-10 | 2025-11-11 | 吉斯凯(苏州)制药有限公司 | 具有杂环结构的化合物、THRβ受体激动剂及用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4017875A4 (en) | 2023-05-03 |
| US12528791B2 (en) | 2026-01-20 |
| JP7646632B2 (ja) | 2025-03-17 |
| JP2025106242A (ja) | 2025-07-15 |
| AU2020336272A1 (en) | 2022-04-14 |
| WO2021041237A1 (en) | 2021-03-04 |
| EP4017875A1 (en) | 2022-06-29 |
| JP2022544714A (ja) | 2022-10-20 |
| CA3154488A1 (en) | 2021-03-04 |
| US20220281849A1 (en) | 2022-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114430743A (zh) | 甲状腺激素受体β激动剂化合物 | |
| JP7846735B2 (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| TWI826525B (zh) | 用於治療特定白血病之化合物 | |
| CN112839655B (zh) | 甲状腺激素受体β促效剂化合物 | |
| CA3093851A1 (en) | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same | |
| JP2024510935A (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| CN103391932B (zh) | 用于抑制pask的杂环化合物 | |
| TW202003472A (zh) | 鈣蛋白酶(calpain)調節劑及其醫療用途 | |
| CN108883122A (zh) | 有用于治疗疾病的c-糖苷化合物 | |
| CN105517549A (zh) | CaMKII抑制剂和其用途 | |
| CN106349233B (zh) | 3,4-二苯基-4h-1,2,4-三唑衍生物及其制备方法和应用 | |
| EA037264B1 (ru) | Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство | |
| JP6838045B2 (ja) | 化合物 | |
| CA3178647A1 (en) | Substituted tricyclic amides, analogues thereof, and methods using same | |
| TW202012414A (zh) | 三環ask1抑制劑 | |
| WO2026058961A1 (en) | Wdr5 inhibitors, compounds, pharmaceutical compositions, and methods of use thereof | |
| HK40091939A (zh) | 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法 | |
| CN115894376A (zh) | 一种芳香族酰胺类化合物、药物组合物及其用途 | |
| HK40052099B (en) | Compounds for treating certain leukemias | |
| HK40052099A (en) | Compounds for treating certain leukemias | |
| HK40012431B (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| HK40012431A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |